MLLC.F Stock Overview
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF3.80 |
| 52 Week High | CHF7.22 |
| 52 Week Low | CHF3.40 |
| Beta | 0.78 |
| 1 Month Change | -7.32% |
| 3 Month Change | n/a |
| 1 Year Change | -41.67% |
| 3 Year Change | -84.73% |
| 5 Year Change | -78.69% |
| Change since IPO | -83.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| MLLC.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | -41.7% | -3.7% | 19.3% |
Return vs Industry: MLLC.F underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: MLLC.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| MLLC.F volatility | |
|---|---|
| MLLC.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MLLC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MLLC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 168 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MLLC.F fundamental statistics | |
|---|---|
| Market cap | US$121.69m |
| Earnings (TTM) | -US$68.10m |
| Revenue (TTM) | US$7.73m |
15.7x
P/S Ratio-1.8x
P/E RatioIs MLLC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLLC.F income statement (TTM) | |
|---|---|
| Revenue | CHF7.04m |
| Cost of Revenue | CHF47.84m |
| Gross Profit | -CHF40.81m |
| Other Expenses | CHF21.18m |
| Earnings | -CHF61.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -1.89 |
| Gross Margin | -579.80% |
| Net Profit Margin | -880.70% |
| Debt/Equity Ratio | 0% |
How did MLLC.F perform over the long term?
See historical performance and comparison